Cargando…

A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura

Immune-mediated thrombotic thrombocytopenic purpura (iTTP), an autoantibody-mediated severe ADAMTS13 deficiency, is caused by insufficient proteolytic processing of von Willebrand factor (VWF) multimers (MMs) and microvascular thrombi. Recurrence of acute iTTP is associated with persistence or reapp...

Descripción completa

Detalles Bibliográficos
Autores principales: Falter, Tanja, Rossmann, Heidi, de Waele, Laure, Dekimpe, Charlotte, von Auer, Charis, Müller-Calleja, Nadine, Häuser, Friederike, Degreif, Adriana, Marandiuc, Dana, Messmer, Xavier, Sprinzl, Martin, Lackner, Karl J., Jurk, Kerstin, Vanhoorelbeke, Karen, Lämmle, Bernhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471935/
https://www.ncbi.nlm.nih.gov/pubmed/37399489
http://dx.doi.org/10.1182/bloodadvances.2023010028
_version_ 1785099962569195520
author Falter, Tanja
Rossmann, Heidi
de Waele, Laure
Dekimpe, Charlotte
von Auer, Charis
Müller-Calleja, Nadine
Häuser, Friederike
Degreif, Adriana
Marandiuc, Dana
Messmer, Xavier
Sprinzl, Martin
Lackner, Karl J.
Jurk, Kerstin
Vanhoorelbeke, Karen
Lämmle, Bernhard
author_facet Falter, Tanja
Rossmann, Heidi
de Waele, Laure
Dekimpe, Charlotte
von Auer, Charis
Müller-Calleja, Nadine
Häuser, Friederike
Degreif, Adriana
Marandiuc, Dana
Messmer, Xavier
Sprinzl, Martin
Lackner, Karl J.
Jurk, Kerstin
Vanhoorelbeke, Karen
Lämmle, Bernhard
author_sort Falter, Tanja
collection PubMed
description Immune-mediated thrombotic thrombocytopenic purpura (iTTP), an autoantibody-mediated severe ADAMTS13 deficiency, is caused by insufficient proteolytic processing of von Willebrand factor (VWF) multimers (MMs) and microvascular thrombi. Recurrence of acute iTTP is associated with persistence or reappearance of ADAMTS13 deficiency. Some patients remain in remission despite recurring or persisting severe ADAMTS13 deficiency. In a prospective 2-year observational study, we investigated VWF MM patterns and ADAMTS13 in patients with iTTP in remission and at acute episodes. Of the 83 patients with iTTP, 16 suffered 22 acute episodes whereas 67 remained in clinical remission during follow-up, including 13 with ADAMTS13 <10% and 54 with ADAMTS13 ≥10%. High -molecular weight to low-molecular weight VWF MM ratio based on sodium dodecyl sulfate-agarose gel electrophoresis was compared with ADAMTS13 activity. VWF MM ratio was significantly higher in patients in remission with <10% compared with ≥10% ADAMTS13 activity. Fourteen samples obtained from 13 to 50 days (interquartile range; median, 39) before acute iTTP onset (ADAMTS13 <10% in 9 patients and 10%-26% in 5) showed VWF MM ratios significantly higher than those from 13 patients remaining in remission with ADAMTS13 <10%. At acute iTTP onset, VWF MM ratio decreased significantly and was low in all patients despite <10% ADAMTS13. The VWF MM ratio does not depend exclusively on ADAMTS13 activity. The disappearance of high molecular weight VWF MMs resulting in low VWF MM ratio at iTTP onset may be explained by consumption of larger VWF MMs in the microcirculation. The very high VWF MM ratio preceding acute iTTP recurrence suggests that VWF processing is hampered more than in patients remaining in remission.
format Online
Article
Text
id pubmed-10471935
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-104719352023-09-02 A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura Falter, Tanja Rossmann, Heidi de Waele, Laure Dekimpe, Charlotte von Auer, Charis Müller-Calleja, Nadine Häuser, Friederike Degreif, Adriana Marandiuc, Dana Messmer, Xavier Sprinzl, Martin Lackner, Karl J. Jurk, Kerstin Vanhoorelbeke, Karen Lämmle, Bernhard Blood Adv Thrombosis and Hemostasis Immune-mediated thrombotic thrombocytopenic purpura (iTTP), an autoantibody-mediated severe ADAMTS13 deficiency, is caused by insufficient proteolytic processing of von Willebrand factor (VWF) multimers (MMs) and microvascular thrombi. Recurrence of acute iTTP is associated with persistence or reappearance of ADAMTS13 deficiency. Some patients remain in remission despite recurring or persisting severe ADAMTS13 deficiency. In a prospective 2-year observational study, we investigated VWF MM patterns and ADAMTS13 in patients with iTTP in remission and at acute episodes. Of the 83 patients with iTTP, 16 suffered 22 acute episodes whereas 67 remained in clinical remission during follow-up, including 13 with ADAMTS13 <10% and 54 with ADAMTS13 ≥10%. High -molecular weight to low-molecular weight VWF MM ratio based on sodium dodecyl sulfate-agarose gel electrophoresis was compared with ADAMTS13 activity. VWF MM ratio was significantly higher in patients in remission with <10% compared with ≥10% ADAMTS13 activity. Fourteen samples obtained from 13 to 50 days (interquartile range; median, 39) before acute iTTP onset (ADAMTS13 <10% in 9 patients and 10%-26% in 5) showed VWF MM ratios significantly higher than those from 13 patients remaining in remission with ADAMTS13 <10%. At acute iTTP onset, VWF MM ratio decreased significantly and was low in all patients despite <10% ADAMTS13. The VWF MM ratio does not depend exclusively on ADAMTS13 activity. The disappearance of high molecular weight VWF MMs resulting in low VWF MM ratio at iTTP onset may be explained by consumption of larger VWF MMs in the microcirculation. The very high VWF MM ratio preceding acute iTTP recurrence suggests that VWF processing is hampered more than in patients remaining in remission. The American Society of Hematology 2023-07-05 /pmc/articles/PMC10471935/ /pubmed/37399489 http://dx.doi.org/10.1182/bloodadvances.2023010028 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Thrombosis and Hemostasis
Falter, Tanja
Rossmann, Heidi
de Waele, Laure
Dekimpe, Charlotte
von Auer, Charis
Müller-Calleja, Nadine
Häuser, Friederike
Degreif, Adriana
Marandiuc, Dana
Messmer, Xavier
Sprinzl, Martin
Lackner, Karl J.
Jurk, Kerstin
Vanhoorelbeke, Karen
Lämmle, Bernhard
A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura
title A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura
title_full A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura
title_fullStr A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura
title_full_unstemmed A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura
title_short A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura
title_sort novel von willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura
topic Thrombosis and Hemostasis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471935/
https://www.ncbi.nlm.nih.gov/pubmed/37399489
http://dx.doi.org/10.1182/bloodadvances.2023010028
work_keys_str_mv AT faltertanja anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT rossmannheidi anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT dewaelelaure anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT dekimpecharlotte anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT vonauercharis anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT mullercallejanadine anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT hauserfriederike anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT degreifadriana anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT marandiucdana anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT messmerxavier anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT sprinzlmartin anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT lacknerkarlj anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT jurkkerstin anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT vanhoorelbekekaren anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT lammlebernhard anovelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT faltertanja novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT rossmannheidi novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT dewaelelaure novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT dekimpecharlotte novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT vonauercharis novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT mullercallejanadine novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT hauserfriederike novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT degreifadriana novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT marandiucdana novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT messmerxavier novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT sprinzlmartin novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT lacknerkarlj novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT jurkkerstin novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT vanhoorelbekekaren novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura
AT lammlebernhard novelvonwillebrandfactormultimerratioasmarkerofdiseaseactivityinthromboticthrombocytopenicpurpura